Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Alaunos Therapeutics, Inc. (TCRT), a leader in T-cell receptor (TCR) cell therapy, announced a poster presentation for its lead Sleeping Beauty TCR-T cell therapy program at the 2023 ASCO Annual Meeting from June 2-6, 2023, in Chicago. The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation study conducted at MD Anderson Cancer Center, focusing on patients with solid tumors, including non-small cell lung and colorectal cancers, who have specific targeted driver mutations. The poster will detail the safety and efficacy of TCR-T cells targeting shared KRAS and TP53 mutations. The presentation is scheduled for June 3, 2023, showcasing Alaunos' advancements in TCR therapy for cancer treatment.
- Advancement in TCR therapy with the lead Sleeping Beauty TCR-T cell therapy program.
- Ongoing Phase 1/2 trial targeting solid tumors with specific driver mutations.
- Presentation at a prominent conference (ASCO) increases visibility and credibility.
- None.
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead non-viral Sleeping Beauty TCR-T cell therapy program in solid tumors at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.
The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation trial being conducted at The University of Texas MD Anderson Cancer Center. The trial is enrolling patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers that have a matching human leukocyte antigen (HLA) whose tumors contain at least one of the targeted driver mutations in KRAS, TP53 and EGFR.
Details of the poster presentation are as follows:
Abstract Title: Safety and Efficacy of Sleeping Beauty TCR-T Cells Targeting Shared KRAS and TP53 Mutations Expressed by Solid Tumors in First-in-Human Phase 1 Study
Session Title: Developmental Therapeutics—Immunotherapy
Session Date and Time: Saturday, June 3, 8:00 a.m. - 11:00 a.m. CT
Abstract Number: 2547
Presenter: Maria Pia Morelli, M.D., Ph.D., Assistant Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at MD Anderson
For more information, visit the ASCO Annual Meeting website.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics is a leader in the science of T-cell receptor (TCR) cell therapy working to revolutionize solid cancer treatment and outcomes. The clinical-stage company’s TCR T-cell therapy (TCR-T) is one of the most advanced TCR programs targeting driver mutations in solid tumors with an ongoing Phase 1/2 trial of its TCR-T product candidates across six solid cancers. Alaunos is powered by two proprietary platforms: its elegantly efficient non-viral Sleeping Beauty cell engineering platform; and its hunTR® discovery platform, which is expanding its industry-leading library of TCRs against high-frequency driver mutations. Alaunos is a part of an ongoing collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), working to advance the science of TCR therapy. For more information, visit www.alaunos.com
Media Contact:
Heather Anderson
6 Degrees PR
handerson@6degreespr.com
Investor Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
FAQ
What is Alaunos Therapeutics' recent announcement regarding TCRT?
When will the ASCO Annual Meeting take place for Alaunos Therapeutics?
What is the focus of the TCR-T Library Phase 1/2 trial conducted by Alaunos?
Who will present the findings of Alaunos' research at ASCO?
